cancer screening test News
-
ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC). The ...
-
GRAIL Receives New York State Approval for Galleri Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced that the New York State Department of Health (NYSDOH) has approved Galleri™, GRAIL’s groundbreaking multi-cancer early detection blood test. With NYSDOH approval, Galleri is now available to residents in the state of New York by prescription to complement existing single cancer screening tests. ...
By Grail, Inc.
-
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2022 and provided a business and financial update. Second quarter Net Revenue was $9.4 million, a 16% decrease as compared to the same period of 2021. During the second quarter the Company was notified by Novitas, it’s CME ...
-
GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, Inc.’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri®, GRAIL’s groundbreaking multi-cancer early ...
By Grail, Inc.
-
American cancer society choose you day engages employers nationwide in focusing on cancer prevention
On May 12, employers nationwide will participate in the American Cancer Society"s first Choose You Day by offering their employees the opportunity to take 30 minutes during the workday to focus on their personal health, and to make a five dollar donation to the Society"s lifesaving work of helping create a world with less cancer and more birthdays. Choose You Day is part of the American Cancer ...
-
Biomark to present validation data of its multianalyte metabolite panel for lung cancer screening at the esmo congress 2022
Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it’s abstract titled “Metabolomic Profiling for the Early Detection of Lung Cancer” has been ...
-
INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market
INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is developing a multi-product ...
By INOVIQ Ltd
-
Biomark provides business update and second quarter financial results
Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to ...
-
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit ...
By Grail, Inc.
-
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in Node-Positive Early-Stage Breast Cancer
Improved quality of care and significant cost savings using the test to guide adjuvant chemotherapy treatment Analysis based on first results from the independent RxPONDER study which identified the majority of women with one to three positive nodes who receive no benefit from chemotherapy Exact Sciences today announced results from a health economic analysis of the Oncotype DX Breast ...
-
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast Cancer Symposium (SABCS) Exact Sciences ...
-
New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score Test to Inform Clinical Decision-making
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the ...
-
Review our webinar: Clinical Validation of HPV assays on the NeuMoDx Platform
Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical cancer HPV screening laboratories. The ...
-
Universal DX Presents Data at EACR Virtual Congress; Top-scoring Poster Shows Accurate Detection of Colorectal Advanced Adenomas
New results from the OMICS study, the company's prospective, international, multi-center study, show Universal DX's blood test can detect colorectal advanced adenomas at 55% sensitivity and 90% specificity, which exceeds currently available non-invasive tests for colorectal cancer screening 80% of sporadic colorectal cancers arise from pre-malignant advanced adenomas, making early detection ...
-
Immundiagnostik`s Colorectal Cancer Screening Portfolio
Regular participation in colorectal cancer (CRC) screening programmes can reduce the number of colorectal cancer cases as well as mortality rates (Brenner et al., 2014; Zorzi et al., 2015)*. Quantitative Fecal Immunochemical Tests (FIT) are recommended for colorectal cancer population screenings. An advantage of quantitative tests is the ability to vary cut-off values, which allows an adaption to ...
-
Cancer Prevention and Early Detection Is One Step Closer as Universal DX Announces Breakthrough Study Results from Its Multi-omics + Computational Biology + Machine Learning Blood Tes
New results from the OMICS study, which will be presented atASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity / 97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ...
-
Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you